transparent gif

 

Ej inloggad.

Göteborgs universitets publikationer

Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT

Författare och institution:
M. Bohm (-); S. M. Lloyd (-); I. Ford (-); J. S. Borer (-); S. Ewen (-); U. Laufs (-); F. Mahfoud (-); J. Lopez-Sendon (-); P. Ponikowski (-); L. Tavazzi (-); Karl Swedberg (Institutionen för medicin, avdelningen för molekylär och klinisk medicin); M. Komajda (-)
Publicerad i:
European Journal of Heart Failure, 18 ( 6 ) s. 672-683
ISSN:
1388-9842
Publikationstyp:
Artikel, refereegranskad vetenskaplig
Publiceringsår:
2016
Språk:
engelska
Fulltextlänk:
Sammanfattning (abstract):
AimsIn heart failure, non-adherence increases events; in turn, the effect of hospitalization on adherence is incompletely understood. We explored the relationship of non-adherence to outcomes, hospitalizations with non-adherence, and the influence of non-adherence on treatment effects of heart rate lowering with ivabradine. Methods and resultsIn the randomized, controlled Systolic Heart failure treatment with the If-inhibitor ivabradine Trial (SHIFT), we studied the effect of non-adherence (n = 1287) compared with adherence (n=5204) on cardiovascular outcomes. After adjustment, non-adherence was associated with the primary composite endpoint of cardiovascular death and heart failure hospitalization (hazard ratio 3.47, 95% confidence interval 2.91-4.13, P < 0.0001). No interaction with the treatment groups of placebo or ivabradine (P for interaction 0.54) occurred. Similar results for cardiovascular death and heart failure hospitalization, as well as for cardiovascular hospitalization, heart failure death, and total death were observed. The effect of ivabradine was maintained in patients being adherent or becoming non-adherent during the trial (P for interaction=0.54). Patients with a previous hospitalization were more likely to become non-adherent thereafter. ConclusionsNon-adherence identifies a group at particularly high cardiovascular event risk independent of treatment allocation. Non-adherent patients in the ivabradine group maintain a treatment benefit. Patients with previous hospitalizations are more likely to become non-adherent and represent a group of particularly high-risk patients in whom special attention to stimulate adherence may be valuable.
Ämne (baseras på Högskoleverkets indelning av forskningsämnen):
MEDICIN OCH HÄLSOVETENSKAP ->
Klinisk medicin
Nyckelord:
Heart failure, SHIFT, Heart rate, Adherence, Cardiovascular hospitalizations, evidence-based pharmacotherapy, medication adherence, follow-up, cardiovascular outcomes, myocardial-infarction, drug adherence, older, patients, double-blind, mortality, association, Cardiovascular System & Cardiology
Postens nummer:
239644
Posten skapad:
2016-07-28 16:42

Visa i Endnote-format

Göteborgs universitet • Tel. 031-786 0000
© Göteborgs universitet 2007